Skip to main content
Advent Life SciencesPress Release

Advent Life Sciences announces the appointment of Mary Kerr as Operating Partner

By 23 September 2015January 5th, 2023No Comments
Press Release.


London, UK. September 23 2015 

Advent Life Sciences announced today the appointment of Mary Kerr as an Operating Partner. Mary joins from GSK, where she has held a range of senior leadership roles most recently as Senior Vice President and Global franchise Leader for GSK’s Immuno-inflammation and Infectious Diseases portfolio. In conjunction with this appointment, Mary will take the role of CEO of NeRRe Therapeutics, a privately held biotechnology company funded by Advent Life Sciences and Novo A/S.




About Advent Life Sciences.

Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs. The investing team consists of 16 professionals, each with extensive scientific, medical and operational experience, a long-standing record of entrepreneurial and investment success in the US and Europe, and is particularly focussed on supporting entrepreneurs and founders to take innovative new medical entities from concept to approval. The Firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies and med tech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US and France.

For more information, please visit

Contact : Advent Life Sciences
Melanie McIntosh
Phone : +44 (0)207 932 2100
email :